ERBB2 and breast cancer: In detail, patients with HER2+ breast cancer and high expression of AKR1C1 had a higher risk of recurrence than did patients with low AKR1C1 expression (Hazard Ratio [HR]=1.53, 95% Confidence Interval [CI] 1.01-2.32, p-value = 0.043).